Home
overview
A unique opportunity to learn from industry experts including:

· Dr Lutz Jermutus, Head, Display Technology Development, Cambridge Antibody Technology
· Michael Roguska, Group Leader, Biologics, Abbott Bioresearch
· Dr Jon Terrett, Director, Molecular Biology, Oxford GlycoSciences
· Dr Joachim Walter, Head, Membrane Separation Sciences, Amersham Biosciences
· Dr Neil Parry, Science Base Leader, Biosciences, Unilever
· Dr Jeremy Wayte, Principal Group Leader, Cell Culture Process Development, Lonza Biologics
· Dr Shana Frederickson, Senior Director, Antibody Discovery, Alexion Antibody Technologies
· Dr Andrew Chapman, Head, BioProcess Research, Celltech
· Dr Geoffrey Davis, Chief Scientific Officer, Abgenix

BENEFITS OF ATTENDING:
· LEARN about novel approaches to engineering synthetic antibodies
· REVIEW the power of complex libraries and display technologies
· HEAR about the evaluation and selection of neutralizing human monoclonal antibodies
· DISCOVER the future of antigen-based cancer immunotherapy
· ASSESS yeast display as a powerful new technology for protein and antibody engineering
· MEET and network with leading industry decision-makers

“This is now becoming the leading European Antibody Conference”
Prof Dr Patrick Baeuerle, Chief Scientific Officer, Micromet
SMi’s Therapeutic Antibody Conference 2002

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jane K Osbourn

Dr Jane K Osbourn, Director of Display Technology, Cambridge Antibody Technology

9:10 PRODUCTION METHODS

Dr Chris Bond

Dr Chris Bond, Postdoctoral Fellow, Department of Medicinal Chemistry, Genentech

  • Identifying an antibody that binds to a disease-related antigen
  • An insight into higher-affinity, higher-specificity and cross-reactive antibody engineering
  • Advantages and disadvantages of different antibody formats
  • Mapping functional binding eptitopes within antigen-binding sites
  • Use of structural and sequence database for improved antibody engineering
  • Identifying sequences required for correct antibody structure
  • 9:40 LINKING ANTIBODY DISPLAY AND HIGH-THROUGHPUT SCREENING FOR THERAPEUTIC ANTIBODY DISCOVERY

    Dr Paula Harrison

    Dr Paula Harrison, Team Leader, Screening Technology Department, Cambridge Antibody Technology

  • Diverse display outputs and HT functional screening enhance the identification of therapeutic candidates
  • Modifying display and HTS strategies to provide an effective lead isolation process
  • Examples of HT screens used to obtain potent, specific leads with the desired biology
  • 10:20 XSTREAM

    Dr Gerald Beste

    Dr Gerald Beste, Director, Combinational Biology, Xerion Pharmaceuticals

  • Chromophore-assisted laser inactivation (CALI) is an efficient protein knockout technology
  • Selection of a scFv-phage display libraries against complex protein mixtures
  • Combination of phage display, CALI and mass spectrometry results in a technology platform for the systematic identification and functional validation of novel drug targets
  • Application example in cancer metastasis
  • 11:00 Morning Coffee

    11:20 DEVELOPMENT OF AN ULTRA POTENT ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS

    Dr Herren Wu

    Dr Herren Wu, Director, Protein Engineering & Structure, MedImmune

  • Systematic enhancement of binding kinetics (koff and kon)
  • Correlation between binding kinetics and in vitro neutralization ability
  • Epitope mapping
  • In vivo potency (cotton rat animal model)
  • Pharmacokinetics and tissue reactivity
  • IND planning
  • 12:00 HUMAN MONOCLONAL ANTIBODIES FOR TREATMENT AND PREVENTION OF VIRAL HEPATITIS

    Dr Shlomo Dagan

    Dr Shlomo Dagan, Chief Scientific Officer, XTL Biopharmaceuticals

  • The development of drug evaluation systems: the in vitro cell-based assay and the Trimera model to assess effective therapies against HBV and HCV
  • Evaluation and selection of neutralizing human monoclonal antibodies for treating viral hepatitis
  • The Trimera mouse as a tool to generate fully human monoclonal antibodies with biological activity
  • HepeX-B, a mixture of two human monoclonal antibodies in phase II clinical trials, treating chronic HBV patients in combination with Lamivudine
  • HepeX-C, a monoclonal antibody to HCV in phase II clinical trials in HCV liver transplant patients to prevent re-infection
  • 12:40 Networking Lunch

    13:40 DERIVING ANTIBODY DRUGS FROM THE HUMAN GENOME

    Dr Vivian Albert

    Dr Vivian Albert, Executive Director, Antibody Development, Human Genome Sciences

  • Use of genomic technologies to identify antibody targets
  • HGS therapeutic antibody programs - Lympho-Stat-B™, a human monoclonal antibody that neutralises B lymphocyte stimulator (BLyS™) bioactivity - Agonist antibodies against TRAIL receptors
  • 14:20 SCREENING OF ANTIBODY LIBRARIES

    Dr Johan Hallborn

    Dr Johan Hallborn, Director, Antibody Discovery, BioInvent

  • Screening of antibody fragments binding to expressed targets on living cells
  • Antibody libraries as a source for finding binders to cellular targets
  • FMAT screening of antibody fragments to surface targets on cells
  • 15:00 ANTIBODY DISCOVERY

    Dr Shana Frederickson

    Dr Shana Frederickson, Senior Director, Antibody Discovery, Alexion Antibody Technologies

  • New method of antibody library construction developed
  • Examples of therapeutically relevant antibodies isolated from the libraries provided
  • Cell-based selections
  • 15:40 Afternoon Tea

    16:00 DISPLAY TECHNOLOGIES

    Dr René Hoet

    Dr René Hoet, Director, Research & Technology, Dyax

  • Generating one or more phage libraries
  • Screening the phage display libraries to select binding compounds with high affinity and high specificity to a target
  • Producing and evaluating the selected binding compounds
  • The diversity of libraries significantly improves the likelihood of identifying compounds with high specificity and high affinity
  • The benefits of parallel screening
  • The advantage of controlled binding and release
  • 16:40 NOVEL CANCER ANTIGEN DISCOVERY FOR IMMUNOTHERAPY

    Dr Jon Terrett

    Dr Jon Terrett, Director, Molecular Biology, Oxford GlycoSciences

  • Conventional oncology antigens
  • Requirements of novel antigens
  • Antigen discovery methods
  • MAb development
  • The future of antigen-based cancer immunotherapy
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Andrew Chapman

    Dr Andrew Chapman, Head, BioProcess Research, Celltech

    9:10 DOWNSTREAM PROCESSING OF RECOMBINANT ANTIBODIES

    Dr Joachim Walter

    Dr Joachim Walter, Head of Membrane Separation Sciences, Amersham Biosciences

  • Development of DSP processes for large scale manufacturing
  • Glycosylation of Ab in high producer cells
  • Maintenance of product quality in DSP processing
  • Technologies for large scale processing
  • 9:40 HIGH LEVEL PRODUCTION OF RECOMBINANT IGG IN THE HUMAN CELL LINE PER.C6TM

    Dr Dirk-Jan Opstelten

    Dr Dirk-Jan Opstelten, Director Cell Technology, Crucell

    10:20 DEVELOPMENT OF NOVEL ANTIBODY FUSION PROTEINS

    Dr Neil Parry

    Dr Neil Parry, Science Base Leader, Biosciences, Unilever

  • Identification and development of llama antibodies
  • Application examples
  • Development of novel fusion proteins for generic applications
  • 11:00 Morning Coffee

    11:20 ALTERNATIVE APPROACHES TO DEVELOPING HIGHLY PRODUCTIVE CELL CULTURE PROCESSES FOR PRODUCING THERAPAUTIC PROTEINS

    Dr Jeremy Wayte

    Dr Jeremy Wayte, Principal Group Leader, Cell Culture Process Development, Lonza Biologics

  • Key factors affecting productivity of cell culture processes
  • Lonza Biologics' three successful alternative approaches to increase the productivity of mammalian cell culture processes - Development of a robust fed-batch process by manipulation of the physiochemical environment - Development of rapid screening protocols - Development of extended cell life
  • 12:00 USING THE XENOMOUSE® TECHNOLOGY FOR THERAPEUTIC PRODUCT LEAD DISCOVERY

  • Overview of the XenoMouse technology
  • Product lead discovery at Abgenix
  • Case studies
  • Process sciences and manufacturing capabilities
  • Dr Larry Green

    Dr Larry Green, Director, Antibody Technologies, Abgenix

    Dr Larry Green

    Dr Larry Green, Director, Antibody Technologies, Abgenix

    12:40 Networking Lunch

    13:40 HIGH AFFINITY SINGLE DOMAIN ANTIBODIES FOR THERAPEUTIC APPLICATIONS

    Dr Hans de Haard

    Dr Hans de Haard, Director, Technology Development, Ablynx

  • Characteristics of Ablynx’ single domain antibodies
  • Large scale production
  • Platform for discovering therapeutics
  • Proteomics applications
  • 14:20 BISPECIFIC T CELL ENGAGER (BiTEs)

    Prof Dr Patrick Baeuerle

    Prof Dr Patrick Baeuerle, Chief Scientific Officer, Micromet

  • IgG1 is a validated and commercially successful antibody format for cancer therapy
  • Recruitment of cytotoxic T cells is not feasible with IgG1
  • BiTEs can recruit and activate T cells
  • BiTEs bypass mechanisms of regular T cell activation
  • MT103 targeting CD19: a first BiTE in the clinic
  • BiTEs can be developed for other targets

    Extreme potency of BiTEs will reduce production costs

  • 15:00 HERCEPTIN

  • Introduction to Herceptin
  • Cardiotoxicity
  • Pharmacokinetic challenges
  • Diagnostics
  • The challenge of targeted therapy: small patient populations = large clinical trial effort
  • Dr Claire Barton

    Dr Claire Barton, Clinical Science Leader, Herceptin, Roche

    Dr Claire Barton

    Dr Claire Barton, Clinical Science Leader, Herceptin, Roche

    15:40 Afternoon Tea

    16:00 PRECLINICAL ISSUES ON DEVELOPMENT OF THERAPEUTIC ANTIBODIES

    Dr Steven W. Martin

    Dr Steven W. Martin, , Amgen

  • Recent technological advances in production of therapeutic antibodies
  • Preclinical development issues and potential solutions
  • Example(s) of the development of a humanized monoclonal antibody
  • 16:40 ANTIBODY ENGINEERING USING YEAST DISPLAY TECHNOLOGY

    Michael Roguska

    Michael Roguska, Group Leader, Biologics, Abbott Bioresearch

  • Display technologies have proven to be valuable research and drug discovery tools
  • Yeast display as a powerful new technology for protein and antibody engineering
  • Yeast display to affinity maturate an scFv to sub-nanomolar affinity using yeast display in conjunction with high-speed fluorescence-activated cell sorting (FACS)
  • Optimizing yeast display library and sorting strategies by examining detection systems and FACS gating parameters
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.